Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors

NCT02012231 is registered in ClinicalTrials.gov with Fore Biotherapeutics as lead sponsor.

NCT NCT02012231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02012231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors
Lead sponsor
Fore Biotherapeutics
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2014
Completion date
June 30, 2015
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal cancer, hairy cell leukemia, histiocytosis, melanoma, non-small cell lung cancer, thyroid cancer